Oramed Pharmaceuticals Inc (ORMP) — Long-term Investment Intensity

Latest as of March 2026: 73.3%

Oramed Pharmaceuticals Inc (ORMP) has a Long-term Investment Intensity of 73.3% as of March 2026. Long-term investments of $197.06 Million represent 73.3% of total assets of $268.85 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check ORMP cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

LT Investment Intensity

73.3%
LT Investments / Total Assets

Long-term Investments

$197.06 Million
USD

Total Assets

$268.85 Million
USD

Country

USA
NASDAQ

Oramed Pharmaceuticals Inc Long-term Investment Intensity (2020–2025)

This chart shows how Oramed Pharmaceuticals Inc's Long-term Investment Intensity has evolved across 6 annual periods from 2020 to 2025. As of March 2026, the intensity stands at 73.3%, reflecting long-term investments of $197.06 Million against total assets of $268.85 Million USD. For the complete balance sheet picture, see Oramed Pharmaceuticals Inc assets under control.

Annual Long-term Investment Intensity for Oramed Pharmaceuticals Inc (2020–2025)

The table below presents the year-by-year Long-term Investment Intensity for Oramed Pharmaceuticals Inc from 2020 to 2025, covering 6 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read ORMP liabilities breakdown for a breakdown of total debt and financial obligations.

Year LT Investment Intensity LT Investments (USD) Total Assets Change (pp)
2025 40.6% $93.74 Million $230.86 Million ▲ +33.6 pp
2024 7.0% $10.91 Million $155.28 Million ▼ -17.9 pp
2023 24.9% $54.93 Million $220.55 Million ▲ +23.2 pp
2022 1.7% $2.70 Million $161.64 Million ▼ -3.6 pp
2021 5.2% $6.69 Million $128.00 Million ▼ -3.6 pp
2020 8.8% $3.93 Million $44.63 Million
pp = percentage points